Best Practice & Research Clinical Rheumatology
Volume 22, Issue 4 , Pages 621-641 , August 2008

Challenges in the management of rheumatoid arthritis in developing countries

  • Girish M. Mody, MBChB (UKZN), MD (Cape Town), FCP (SA), FRCP (London) (Fellow of the University of Kwa Zulu-Natal, and Aaron Beare Family Professor of Rheumatology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +27 31 2604284; Fax: +27 31 2604482.
  • Mario H. Cardiel, MD, MSc, FACR (Jefe de la Unidad de Investigación ‘Dr Mario Alvizouri Muñoz’)

References 

  1. Cardiel MH. First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology (Oxford). 2006 Jun;45(supplement 2):ii7–ii22
  2. Organización Panamericana de la Salud . La Salud en las Américas. In: SaludOPdl  editors. Publicación científica y técnica N° 587. vol. 1:Washington, DC: Organización Mundial de la Salud; 2002;
  3. Sihvonen S, Korpela M, Laippala P, et al. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scandinavian Journal of Rheumatology. 2004;33(4):221–227
  4. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Seminars in Arthritis and Rheumatism. 2000 Apr;29(5):305–320
  5. Abdel-Nasser AM, Rasker JJ, Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 1997 Oct;27(2):123–140
  6. Davatchi F. Rheumatic diseases in the APLAR region. APLAR Journal of Rheumatology. 2006;9:5–10
  7. Spindler A, Bellomio V, Berman A, et al. Prevalence of rheumatoid arthritis in Tucuman, Argentina. The Journal of Rheumatology. 2002 Jun;29(6):1166–1170
  8. Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clinical and Experimental Rheumatology. 2002 Sep–Oct;20(5):617–624
  9. Senna ER, De Barros AL, Silva EO, et al. Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. The Journal of Rheumatology. 2004 Mar;31(3):594–597
  10. Moolenburgh JD, Moore S, Valkenburg HA, Erasmus MG. Rheumatoid arthritis in Lesotho. Annals of the Rheumatic Diseases. 1984 Feb;43(1):40–43
  11. Meyers OL, Daynes G, Beighton P. Rheumatoid arthritis in a tribal Xhosa population in the Transkei, Southern Africa. Annals of the Rheumatic Diseases. 1977 Feb;36(1):62–65
  12. Solomon L, Beighton P, Valkenburg HA, et al. Rheumatic disorders in the South African Negro. Part I. Rheumatoid arthritis and ankylosing spondylitis. South African Medical Journal = Suid-Afrikaanse tydskrif vir geneeskunde. 1975 Jul 26;49(32):1292–1296
  13. Beighton P, Solomon L, Valkenburg HA. Rheumatoid arthritis in a rural South African Negro population. Annals of the Rheumatic Diseases. 1975 Apr;34(2):136–141
  14. Solomon L, Beighton P, Valkenburg HA, Robin G. Proceedings: rheumatoid arthritis in the South African Negro. Annals of the Rheumatic Diseases. 1975 Oct;34(5):463–464
  15. Mody GM, Hammond MG, Naidoo PD. HLA associations with rheumatoid arthritis in African blacks. Journal of Rheumatology. 1989 Oct;16(10):1326–1328
  16. Pile KD, Tikly M, Bell JI, Wordsworth BP. HLA-DR antigens and rheumatoid arthritis in black South Africans: a study of ethnic groups. Tissue Antigens. 1992 Mar;39(3):138–140
  17. Martell RW, du Toit ED, Kalla AA, Meyers OL. Association of rheumatoid arthritis with HLA in three South African populations-whites, blacks and a population of mixed ancestry. South African Medical Journal. 1989 Sep 2;76(5):189–190
  18. Martell RW, Stein M, Davis P, et al. The association between HLA and rheumatoid arthritis in Zimbabwean blacks. Tissue Antigens. 1990 Sep;36(3):125–126
  19. Okoye RC, Ollier W, Jaraquemada D, et al. HLA-D region heterogeneity in a Nigerian population. Tissue Antigens. 1989 Apr;33(4):445–456
  20. Ruiz-Morales JA, Vargas-Alarcon G, Flores-Villanueva PO, et al. HLA-DRB1 alleles encoding the ‘shared epitope’ are associated with susceptibility to developing rheumatoid arthritis whereas HLA-DRB1 alleles encoding an aspartic acid at position 70 of the beta-chain are protective in Mexican Mestizos. Human Immunology. 2004 Mar;65(3):262–269
  21. Angulo J MT, Ponce de León H, et al. Epitope Reumatoide y alelo HLA-DRB1*0404 se asocian con susceptibilidad para artritis reumatoide en mestizos peruanos, alelo HLA-DRB1*1402 en duda y la combinación maligna *0401/0404 ausente. Revista Peruana de Reumatología. 2003;9:26–32
  22. Delgado-Vega AM, Anaya JM. Meta-analysis of HLA-DRB1 polymorphism in Latin American patients with rheumatoid arthritis. Autoimmunity Reviews. 2007 Jun;6(6):402–408
  23. Malaviya AN, Mehra NK, Dasgupta B, et al. Clinical and immunogenetic studies in rheumatoid arthritis from northern India. Rheumatology International. 1983;3(3):105–108
  24. Zhao Y, Dong Y, Zhu X, Qiu C. HLA-DRB1 alleles genotyping in patients with rheumatoid arthritis in Chinese. Chinese Medical Sciences Journal = Chung-kuo i hsueh k'o hsueh tsa chih/Chinese Academy of Medical Sciences. 1996 Dec;11(4):232–235
  25. Kong KF, Yeap SS, Chow SK, Phipps ME. HLA-DRB1 genes and susceptibility to rheumatoid arthritis in three ethnic groups from Malaysia. Autoimmunity. 2002 Jul;35(4):235–239
  26. Massardo L, Aguirre V, Garcia ME, et al. Clinical expression of rheumatoid arthritis in Chilean patients. Seminars in Arthritis and Rheumatism. 1995 Dec;25(3):203–213
  27. Mody GM. Rheumatoid arthritis in the Western Cape – a clinical study. MD thesis, University of Cape Town; 1987.
  28. Tikly M, Zannettou N, Hopley M. A longitudinal study of rheumatoid arthritis in South Africans. Medscape General Medicine. 2003 Feb 5;5(1):2
  29. Adebajo AO, Reid DM. The pattern of rheumatoid arthritis in West Africa and comparison with a cohort of British patients. The Quarterly Journal of Medicine. 1991 Aug;80(292):633–640
  30. Anaya JM, Correa PA, Mantilla RD, et al. Rheumatoid arthritis in African Colombians from Quibdo. Seminars in Arthritis and Rheumatism. 2001 Dec;31(3):191–198
  31. Cadena J, Vinaccia S, Perez A, et al. The impact of disease activity on the quality of life, mental health status, and family dysfunction in Colombian patients with rheumatoid arthritis. Journal of Clinical Rheumatology. 2003 Jun;9(3):142–150
  32. Benitha R, Tikly M. Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus. Clinical Rheumatology. 2007 Jan;26(1):24–29
  33. Haroon N, Aggarwal A, Lawrence A, et al. Impact of rheumatoid arthritis on quality of life. Modern Rheumatology. 2007;17(4):290–295
  34. Concha M AX, Salas J. La carga de enfermedad en Chile. Proyecto de Prioridades de inversión en Salud. Ministerio de Salud, República de Chile. Santiago de Chile. 1996;1–62
  35. Martinez I. Costos de la Artritis Reumatoide en Venezuela. Reumatología. Caracas: Universidad Bolivariana; 1997;
  36. Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH. Direct costs of medical attention to Mexican patients with rheumatoid arthritis in a tertiary care center. Clinical and Experimental Rheumatology. 1997 Jan–Feb;15(1):75–78
  37. Audisio MJ, Strusberg I, Orellana Barrera SD, et al. [Semester direct cost by rheumatoid arthritis in patients in a university hospital]. Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina). 2003;60(2):35–41
  38. Osiri M, Maetzel A, Tugwell P. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand. The Journal of Rheumatology. 2007 Jan;34(1):57–63
  39. Loza E, Abasolo L, Clemente D, et al. Variability in the use of orthopedic surgery in patients with rheumatoid arthritis in Spain. The Journal of Rheumatology. 2007 Jul;34(7):1485–1490
  40. Mody Gm LI, Meyers OL, Reinach SG, Heywood AWB. Surgical requirements in rheumatoid arthritis. Journal of Orthopaedic Rheumatology. 1988;1:165–172
  41. Massardo L, Gabriel SE, Crowson CS, et al. A population based assessment of the use of orthopedic surgery in patients with rheumatoid arthritis. The Journal of Rheumatology. 2002 Jan;29(1):52–56
  42. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis and Rheumatism. 2002 Sep;46(9):2287–2293
  43. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis and Rheumatism. 2002 Sep;46(9):2294–2300
  44. Edwards CJ, Cooper C, Fisher D, et al. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2007 Oct 15;57(7):1151–1157
  45. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford, England). 2007 Jul;46(7):1157–1160
  46. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. The Journal of Rheumatology. 2008 Mar;35(3):387–393
  47. Jenks KA, Stamp LK, O'Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. The Journal of Rheumatology. 2007 Nov;34(11):2201–2203
  48. Hernandez-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. The Journal of Rheumatology. 1998 Oct;25(10):1900–1907
  49. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. The Journal of Rheumatology. 2007 Apr;34(4):706–711
  50. Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Current Opinion in Rheumatology. 2007 Nov;19(6):619–625
  51. Calabrese LH. Emerging viral infections and arthritis: the role of the rheumatologist. Nature Clinical Practice. 2008 Jan;4(1):2–3
  52. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Annals of the Rheumatic Diseases. 2007 Nov;66(supplement 3):iii2–iii22
  53. Duvic M, Johnson TM, Rapini RP, et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Archives of Dermatology. 1987 Dec;123(12):1622–1632
  54. Roland ME, Stock PG. Solid organ transplantation is a reality for patients with HIV infection. Current HIV/AIDS Reports. 2006 Sep;3(3):132–138
  55. Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. The New England Journal of Medicine. 2003 Jun 5;348(23):2323–2328
  56. Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumor necrosis factor therapy in HIV positive individuals with rheumatic disease. Annals of the Rheumatic Diseases. 2008;67:710–712
  57. Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine. 2007 Mar;74(2):197–200
  58. Kalla AA, Tikly M. Rheumatoid arthritis in the developing world. Best Practice & Research. Clinical Rheumatology. 2003 Oct;17(5):863–875
  59. Sanchez G, Castro JS, Snih SA, et al. Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. Rheumatology International. 2007 Apr;27(6):531–536
  60. Das SK, Pareek A, Mathur DS, et al. Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial-an Indian experience. Current Medical Research and Opinion. 2007 Sep;23(9):2227–2234
  61. Davatchi F AM, Shahram F, Nadji A, et al. DMARD Combination therapy in rheumatoid arthritis: 5 year follow-up results in a daily practice setting. APLAR Journal of Rheumatology. 2006;9:60–63
  62. Gaitonde S, Pathan E, Sule A, et al. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Annals of the Rheumatic Diseases. 2002 Mar;61(3):251–253
  63. Goycochea-Robles MV, Arce-Salinas CA, Guzman-Vazquez S, Cardiel-Rios MH. Prescription rheumatology practices among Mexican specialists. Archives of Medical Research. 2007 Apr;38(3):354–359
  64. Caballero Uribe Cv LJ, Philippe Chalem P. Tratamiento de la artritis reumatoide en Colombia. Aplicación práctica de los conceptos teóricos por parte de los reumatólogos colombianos. Revista Colombiana de Reumatología. 2002;9:242–250
  65. Thong Byh VS, Koh ET. The use of anti-tumour necrosis factor -alpha therapies for rheumatoid arthrtis in Singapore. APLAR Journal of Rheumatology. 2006;9:150–156
  66. Hur Jw CC, Bae SC. Clinical experience with tumour necrosis factor blockers in Korean patients with rheumatoid arthrtis. APLAR Journal of Rheumatology. 2006;9:146–149
  67. Kumar A. Experience with anti-tomur necrosis factor alpha therapy in India. APLAR Journal of Rheumatology. 2006;9:136–141
  68. Navarra Sv RA, Lichauco JJ, Tan PP. Clinical experience with infliximab among Filipino patients with rheumatic diseases. APLAR Journal of Rheumatology. 2006;9:150–156
  69. Zhang Fc HY, Huang F, Wu DH, et al. Infliximab versus placebo in rheumatoid arthrtis patients receiving concomitant methotrexate: a preliminary study. APLAR Journal of Rheumatology. 2006;9:127–130
  70. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Annals of the Rheumatic Diseases. 2003 Nov;62(supplement 2):ii2–ii9
  71. Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford, England). 2007 Feb;46(2):327–334
  72. Winthrop KL. Serious infections with antirheumatic therapy: are biologicals worse?. Annals of the Rheumatic Diseases. 2006 Nov;65(supplement 3):iii54–iii57
  73. Strangfeld A, Listing J. Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Practice & Research. 2006 Dec;20(6):1181–1195
  74. Madariaga MG, Jalali Z, Swindells S. Clinical utility of interferon gamma assay in the diagnosis of tuberculosis. Journal of the American Board of Family Medicine. 2007 Nov–Dec;20(6):540–547
  75. Winthrop KL, Siegel JN, Jereb J, et al. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis and Rheumatism. 2005 Oct;52(10):2968–2974
  76. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005 Oct;60(10):800–805
  77. Greenberg JD, Reddy SM, Schloss SG, et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. Journal of Rheumatology. 2008 May;35(5):770–775
  78. Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recommendation Reports. 2005 Dec 16;54(RR-15):49–55
  79. Ponce de Leon D, Acevedo-Vazquez E, Alvizuri S, et al. Comparison of the Interferon -gamma assay with the tuberculin skin testing for the detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB – endemic population. Journal of Rheumatology. 2008 May;35(5):776–781
  80. Mok CC. Consensus on the use and monitoring of anti-TNF-alpha therapies for rheumatic diseases in Hong Kong 2005 Hong Kong Society for Rheumatology. APLAR Journal of Rheumatology. 2006;9:175–180
  81. Lichauco JJT, Tankeh-Torres SA, Navarra SV. Dans LF for the Task Force for TB Screening Prior to the Use of Biologic Agents. Phillipine guidelines on the screening for tuberculosis prior to the use of biological agents. APLAR Journal of Rheumatology. 2006;9:184–192
  82. Handa R MR, Chaturvedi VP, Pispati PK, et al. Guidelines for tuberculosis prophylaxis during anti-tumour factor - alpha treatment: Indian Rheumatology Association. APLAR Journal of Rheumatology. 2006;9:181–183
  83. Rheumatology MCHKSf . Consensus on the use and monitoring of anti-TNF-Alpha therapies for rheumatic diseases in Hong Kong 2005. APLAR Journal of Rheumatology. 2006;9:175–180
  84. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis and Rheumatism. 2003 Aug;48(8):2122–2127
  85. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis and Rheumatism. 2007 Jun 15;57(5):756–761
  86. Gomez-Reino J, Carmona L. Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists. Acta Reumatologica Portuguesa. 2006 Jul–Sep;31(3):201–203
  87. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007 Dec 1;370(9602):1861–1874
  88. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2007 Feb;66(2):143–150
  89. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Annals of the Rheumatic Diseases. 2007 Feb;66(2):228–234
  90. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis and Rheumatism. 2006 Sep;54(9):2807–2816
  91. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Annals of the Rheumatic Diseases 2008 Jan 18 [Epub ahead of print].

PII: S1521-6942(08)00051-X

doi: 10.1016/j.berh.2008.04.003

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 4 , Pages 621-641 , August 2008

Article Tools

* Image Usage & Resolution